CERTIFICATION OF FACSIMILE TRANSMISSION I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below. Type or print name of person signing certification Signature Date

<u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Jeffrey Alan Dodge Group Art Unit:

International Application Date: January 18, 2005 Conf No.:

For: SELECTIVE ESTROGEN RECEPTOR MODULATORS

Docket No.: X16065

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/Gilbert T. Voy/

Gilbert T. Voy Attorney for Applicants Registration No. 43,972 Phone: 317-276-2966

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

June 20, 2006

FORM PTO 1449 (modified)	Atty. Docket No.	Serial No
	X-16065	
INFORMATION DISCLOSURE CITATION	First Applicant	
IN AN APPLICATION	Jeffrey Alan Dodge	
	Application Date	Group Art Unit
	US Nat'l Entry (if applicable)	

Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines
	No. 1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Page or Relevant Figures Appear
	AA	US			
	AB	US			

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴⁻ Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	EP 0 761 669	03-12-1997	Eli Lilly and Company	Page 43; example 11b	
	BB	WO 03/053977	07-03-2003	Ortho-McNeil Pharmaceutical, Inc.	Claim l	
	BC	EP 0 761 659	03-12-1997	Eli Lilly and Company	Page 1, Line 3 – 7; examples 2, 5, 6	
	BD	WO 95/10513	04-20-1995	Pfizer Inc.; et al.	Table 2, p. 76, 2 nd structural formula; p. 77, 2 nd structural formula abstract; example 19	
	BE	EP 0 729 951	09-04-1996	Eli Lilly and Company	The whole document	
	BF	EP 0 731 100	09-11-1996	Eli Lilly and Company	The whole document	
	BG	EP 0 791 591	08-27-1997	Eli Lilly and Company	Examples p. 5, line 52 - line 54; claim 1	

Examiner	Date Considered	
Signature		

^{**}EXAMINER. Initial if reference considered, whether or not criation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional) ² See Kinds Codes of USPTO Patent Documents at <u>wow usplo gov</u> or MPEP 901 04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ² For Tapacese partent documents, the indication of the typer of the Engage of

FORM PTO 1449 (modified)	Atty. Docket No. X-16065	Serial No		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Jeffrey Alan Dodge			
	Application Date US Nat'l Entry (if applicable)	Group Art Unit		

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, syuposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	Т6
	CA	Grese T. A., et al., "Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators", <i>Journal of Organic Chemistry</i> , Washington, USA, vol. 41, no. 8, pages 1272-1283, 1998.	
	СВ	Grese T. A., et al., "Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-Arylbenzothiophene core of raloxifene" <i>Journal of Medicinal Chemistry</i> , American Chemical Society, vol. 40, no. 2, pages 146-167, 1997.	
	CC		
	CD		
	CE		
	CF		
	CG		
	СН		
	CI		
	CJ		
	CK		
	CL		
	CM		

Examiner	Date Considered		
Signature			

^{**}EXAMINER. Initial if reference considered, whether or not criation is ra conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² See Kinds Codes of USPTO Patent Documents at <u>wow usplo gov</u> or MPEP 901 04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ² For Tapacese partent documents, the indication of the type of the Engage of t